This trial is already open in the United States, and I believe some on this forum are participating. This announcemment indicates that the company is also opening clinical trial sites across the EU. I checked clnicaltrials.gov but they have not listed the EU sites yet.
prnewswire.com/news-release...
clinicaltrials.gov/ct2/show...
I am cautiously optimistic about this trial because they had positive statistically significant results in Phase 2 with this drug for Parkinson's Disease and this is a large Phase 3 trial that is moving fast. The company is planning an interim analysis in Quarter 2 of this year (2023) to assess whether the number of subjects planned to enroll is adequate. We should have some answers (i.e., does it work in a clinically meaningful way and is it safe) about this drug around the end of 2024/beginning of 2025.